Analyst Price Targets — INMD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 11, 2026 12:03 pm | Jeff Johnson | Robert W. Baird | $17.00 | $14.62 | TheFly | InMode price target raised to $17 from $16 at Baird |
| December 17, 2025 12:15 pm | — | Canaccord Genuity | $15.00 | $14.48 | TheFly | InMode price target lowered to $15 from $16 at Canaccord |
| April 14, 2025 5:13 pm | Matthew Taylor | Jefferies | $15.00 | $15.08 | TheFly | InMode price target lowered to $15 from $16 at Jefferies |
| October 16, 2024 4:06 pm | Sam Elber | BTIG | $25.00 | $16.88 | StreetInsider | BTIG Starts InMode Ltd. (INMD) at Buy |
| October 12, 2024 5:23 pm | Matt Miksic | Barclays | $27.00 | $16.50 | TheFly | InMode price target lowered to $27 from $29 at Barclays |
| July 23, 2024 5:00 am | Matthew Taylor | Jefferies | $19.00 | $17.75 | TheFly | InMode downgraded to Hold from Buy at Jefferies |
| July 12, 2024 6:30 am | Caitlin Cronin | Canaccord Genuity | $16.00 | $16.82 | TheFly | InMode price target lowered to $16 from $21 at Canaccord |
| May 3, 2024 7:06 am | Danielle Antalffy | UBS | $20.00 | $17.36 | StreetInsider | InMode Ltd. (INMD) PT Lowered to $20 at UBS |
| October 13, 2023 2:11 pm | Caitlin Cronin | Canaccord Genuity | $22.00 | $20.75 | Benzinga | InMode Faces Revenue Headwinds Amid Challenging Economics: Analyst Cuts Price Target And Estimates |
| December 21, 2022 7:00 am | — | Barclays | $44.00 | $35.22 | Benzinga | Barclays Initiates Coverage On InMode with Overweight Rating, Announces Price Target of $44 |
Latest News for INMD
YOKNEAM, Israel, Feb. 26, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences in March: Barclays 28th Annual Global Healthcare Conference Presenters: Yair Malca, Chief Financial Officer Format: In-person fireside chat moderated by Matt Miksic, Senior Equity Analyst, and one-on-one…
The committee, formed by InMode's board, evaluated multiple proposals for a potential transaction with help from outside financial and legal advisers. After reviewing the final bids, it concluded that none were adequate or in the best interests of the company and its shareholders, and decided to discontinue the process.
YOKNEAM, Israel, Feb. 23, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) a leading global provider of innovative medical technologies ("InMode" or the "Company"), today announced that the independent transaction committee of its Board of Directors (the "Committee") has completed its review of proposals received in connection with a potential transaction.
InMode Ltd. remains a Strong Buy at current levels, supported by a robust balance sheet, proprietary technology, and international growth. Green shoots include a 2.7% rise in consumables/servicing revenue and 14.5% international sales growth, offsetting possible U.S. market saturation. Management guides for flat 2026 revenue, with new product launches and expanding international footprint positioning INMD for future…
InMode Ltd. (INMD) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for INMD.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.